Back to top
more

Tandem Diabetes Care (TNDM)

(Real Time Quote from BATS)

$33.24 USD

33.24
655,654

+0.39 (1.19%)

Updated Nov 5, 2024 03:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth C Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Integra LifeSciences (IART) Q3 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Integra (IART) delivered earnings and revenue surprises of -2.56% and 1.35%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Tandem Diabetes Care, Inc. (TNDM) Soars 6.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors remain optimistic about Tandem Diabetes (TNDM), backed by strategic developments and innovative new launches.

Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for XHE

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) due to the t:slim X2 insulin pump and new product innovations.

Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?

by Zacks Equity Research

Sector ETF report for XHE

Tandem Diabetes (TNDM) Reports Narrower Q2 Loss, Trims '23 View

by Zacks Equity Research

Tandem Diabetes' (TNDM) second-quarter 2023 performance reflects new technology innovations and operational improvements throughout its business.

Compared to Estimates, Tandem Diabetes Care, Inc. (TNDM) Q2 Earnings: A Look at Key Metrics

by Zacks Equity Research

Although the revenue and EPS for Tandem Diabetes Care, Inc. (TNDM) give a sense of how its business performed in the quarter ended June 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Tandem Diabetes Care, Inc. (TNDM) Reports Q2 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 44.44% and 2.83%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Tandem Diabetes (TNDM) Gets FDA Nod for Tandem Mobi System

by Zacks Equity Research

Tandem Diabetes (TNDM) receives FDA clearance for the world's smallest AID system, Tandem Mobi.

Strength Seen in Tandem Diabetes Care, Inc. (TNDM): Can Its 8.9% Jump Turn into More Strength?

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

Here's Why You Should Retain Tandem Diabetes (TNDM) Now

by Zacks Equity Research

Investors continue to be optimistic about Tandem Diabetes (TNDM) based on the strong performance of the t:slim X2 insulin pump.

Tandem Diabetes (TNDM) Q1 Earnings Miss, Gross Margin Dips

by Zacks Equity Research

According to Tandem Diabetes (TNDM), Q1 revenues are in line with the high end of its expectations.

Tandem Diabetes Care, Inc. (TNDM) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -12.50% and 1.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Will KORU Medical Systems Inc. (KRMD) Report Negative Earnings Next Week? What You Should Know

by Zacks Equity Research

KORU Medical Systems Inc. (KRMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: Tandem Diabetes Care, Inc. (TNDM) Q1 Earnings Expected to Decline

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Tandem Diabetes (TNDM) Gains on Pump Sales, Margin Woe Stays

by Zacks Equity Research

Tandem Diabetes (TNDM) is now increasing its renewal numbers both in volume and rates.

Why Is Masimo (MASI) Up 0.2% Since Last Earnings Report?

by Zacks Equity Research

Masimo (MASI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tandem Diabetes (TNDM) Releases Favorable Data on t:slim X2

by Zacks Equity Research

Tandem Diabetes (TNDM) demonstrated positive results from the clinical trial of advancing its Control-IQ technology to younger age group patients.

Tandem Diabetes (TNDM) Q4 Earnings Beat, Gross Margin Dips

by Zacks Equity Research

Tandem Diabetes (TNDM) Q4 GAAP sales reflect an accounting deferral related to the recent introduction of the company's Tandem Choice program in the United States.

Tandem Diabetes Care, Inc. (TNDM) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of 50% and 1.06%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Mesa Labs (MLAB) Tops Q3 Earnings Estimates

by Zacks Equity Research

Mesa Labs (MLAB) delivered earnings and revenue surprises of 11.90% and 5.95%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

Tandem (TNDM) to Expand Global Insulin Pump Base With New Buy

by Zacks Equity Research

The AMF Medical acquisition will help Tandem (TNDM) advance with its sustainability objectives by offering an additional pump that minimizes electronic and battery waste generation.

Tandem Diabetes (TNDM) Q3 Earnings Miss, Sales View Cut

by Zacks Equity Research

Tandem Diabetes (TNDM) defers $0.6 million of United States pump sales as a result of Tandem Choice.

Tandem Diabetes Care, Inc. (TNDM) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Tandem Diabetes Care, Inc. (TNDM) delivered earnings and revenue surprises of -800% and 0.65%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?